Life Sciences

insitro models added to Lilly TuneLab

insitro and Eli Lilly made machine-learning models for small-molecule property and in-vivo pharmacokinetic prediction available to selected biotech users through Lilly TuneLab.

insitro announced that machine-learning models developed with Eli Lilly for predicting small-molecule properties, including in-vivo pharmacokinetic behavior, are available to certain biotechnology companies through Lilly TuneLab. The models are intended to support earlier assessment of drug candidates and improve computational decision-making in small-molecule development. The announcement connects an AI developer, a major pharmaceutical company, and a platform intended for external biotech use. The source does not provide outcome data showing that the models have improved clinical success rates or reduced development timelines. It also does not specify the participating biotech companies or commercial access terms in the available excerpt.

Original source: Business Wire via Yahoo Finance

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI